多发性骨髓瘤
医学
多中心研究
肿瘤科
生活质量(医疗保健)
质量(理念)
内科学
随机对照试验
护理部
哲学
认识论
作者
Ali İhsan Gemici,İstemi SERİN,Vedat Buğra EROL,Mehmet Hilmi Doğu,İdris İNCE,Rafet Eren,Atakan TEKİNALP,Volkan Karakuş,İklil Nur KOÇ EROL,Zeynep Ece ARSLAN,Zekiye Nur TAY,Elif Nur TUNCER,Ömür Gökmen Sevindik
出处
期刊:Forbes tıp dergisi
[Logos Medical Publication]
日期:2022-08-05
卷期号:3 (2): 165-172
标识
DOI:10.4274/forbes.galenos.2022.04274
摘要
Objective: Both the length of the treatment period and the diversity of the agents used in the treatment significantly affect the quality of life (QoL) of the patients with multiple myeloma (MM).With the aid of the EORTC Quality of Life Questionnaire Consisting of 30 Questions "EORTC QLQ-C30" and the Quality of Life Questionnaire Multiple Myeloma Module "QLQ-MY20", we aimed to obtain data on quality of life in MM patients in a representative sample of the general population of our country.Methods: One hundred sixty eight patients from 6 different centers followed between 2018-2020 were included in the study.The QLQ-C30, and the QLQ-MY20 questionnaires specific for MM patients were used and the results were reported statistically.Results: Seventy eight (46%) of the patients were female, while 90 (54%) were male.The median age was 64 (22-84).When the findings were analysed, it was found that there was a greater effect on the symptom scale compared to the functional scale. Conclusion:The importance of the treatment-related side effect management, together with the adequate administration of appropriate symptomatic treatment in holistic treatment management were emphasized as effective factors in terms of the QoL of patients with MM.
科研通智能强力驱动
Strongly Powered by AbleSci AI